FORUS Therapeutics is thrilled to announce Weihao Tang as Senior Product Manager. Weihao brings more than 10 years of experience across the pharmaceutical and clinical diagnostics industries, combining a strong scientific foundation with broad commercial expertise....

FORUS Therapeutics is thrilled to announce Marie-Eve Caron as Associate Director, Sales. Marie-Eve brings more than 20 years of pharmaceutical experience, including over 13 years in specialty care across immunology and hematology/oncology. Throughout her career, she...

(OAKVILLE, Ontario) July 6, 2026 ­– FORUS Therapeutics Inc (“FORUS”), a wholly owned subsidiary of PharmaEssentia Corp, is pleased to announce that it has received a Notice of Compliance (NOC) authorizing BESREMI® (ropeginterferon alfa-2b) for the treatment of adults...

(OAKVILLE, Ontario) June 11, 2026 ­– FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and...

We are pleased to announce that Marie-Josèphe Champagne has returned to FORUS as Senior Medical Science Liaison (MSL) for Quebec and Atlantic. Marie-Josèphe brings extensive experience from her recent role as National MSL Manager for Hematology, along with more than a...

FORUS Therapeutics Inc. is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Quebec as of November 6th. Further details on the criteria can be found in the links below: Liste des médicaments - Établissement - en vigueur le 6 novembre 2025 Liste...

FORUS Therapeutics is thrilled to welcome Lisa Kolomaya as Therapeutic Area Manager, Hematology/Oncology, AB/SK. Lisa is a results-driven life sciences professional with extensive expertise in both oncology and hematology. Guided by a strategic mindset and passion for...

FORUS Therapeutics is thrilled to welcome Erin Webb as Therapeutic Area Manager, Hematology/Oncology, SW ON. Erin began her career as a physician assistant in the US, caring for patients with both benign and malignant hematologic conditions as well as managing...

FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation. Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health...

FORUS Therapeutics Inc. and PharmaEssentia Corporation have entered into an exclusive licensing agreement for the registration and distribution of BESREMi® (ropeginterferon alfa-2b) for the treatment of polycythemia vera (PV), in Canada. Under the terms of the...

FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas - including over 15 years in hematology and oncology....

FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...